Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
Financing extension led by 8VC to advance LTS-201 as a potential significant commercial opportunity in Huntington’s disease (IND expected in 3Q 2026) Potential clinical proof-of-concept of Latus platform from LTS-101 in CLN2 disease expected in…